Kielgast, U., Krarup, T., Holst, J. J., & Madsbad, S. (2011). Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function. American Diabetes Association.
Chicago-stil citatKielgast, Urd, Thure Krarup, Jens Juul Holst, och Sten Madsbad. Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function. American Diabetes Association, 2011.
MLA-referensKielgast, Urd, Thure Krarup, Jens Juul Holst, och Sten Madsbad. Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function. American Diabetes Association, 2011.